FINWIRES · TerminalLIVE
FINWIRES

カナダ国立銀行は、実物資産セクターの投資判断を「パフォーム」に据え置き、目標株価を7.50ドルに引き上げた。

By

-- カナダ国立銀行は金曜日、リアル・マターズ(REAL.TO)の株式について、セクター・パフォームのレーティングを維持するとともに、目標株価を7.00ドルから7.50ドルに引き上げた。これは、同社が第2四半期決算で連結純利益を計上したことを受けた措置である。 アナリストらは、リアル・マターズが米国不動産権原事業で顧客を継続的に獲得しており、その多くは同社の大規模な米国不動産鑑定事業の顧客基盤からのものだと指摘した。同社は第2四半期に4社の新規顧客を獲得し、その中には大手非銀行系サービサーも含まれている。さらに四半期末には、ティア1の融資機関3社目と、上位100社に入る融資機関1社と契約を締結した。 こうした勢いが力強い成長を牽引し、純収益は前年同期比176%増の330万ドル、調整後EBITDAは前年同期のマイナス210万ドルからマイナス40万ドルに改善した。アナリストらは、不動産権原事業は現在、総純収益の約25%を占めているものの、不動産鑑定事業と同等の規模にまで拡大する可能性があると付け加えた。 「総じて、第2四半期の業績は堅調であり、米国における不動産権原事業の規模拡大、市場シェアの拡大(鑑定および権原調査の両分野)、そして営業レバレッジの向上という同社の戦略実行を反映していると考えています。とはいえ、金利環境の不確実性は依然としてリスクとリターンのバランスを崩す要因となっています」とアナリストは述べています。

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.

$GEHC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.

$LII